Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Collaboration revenue				$ 19,306
Operating expenses:
Research and development	$ 17,730	$ 17,193	$ 33,520	32,861
General and administrative	4,327	4,659	9,228	8,691
Total operating expenses	22,057	21,852	42,748	41,552
Loss from operations	(22,057)	(21,852)	(42,748)	(22,246)
Other income, net	755	347	1,833	727
Net loss before income taxes	(21,302)	(21,505)	(40,915)	(21,519)
Benefit (Provision) for income taxes	(2)	6	(18)	88
Net loss	(21,304)	(21,499)	(40,933)	(21,431)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale debt securities	10	59	(107)	180
Total comprehensive loss	(21,294)	(21,440)	(41,040)	(21,251)
Net loss	(21,304)	(21,499)	(40,933)	(21,431)
Less: accretion of preferred stock to redemption value		(19)		(39)
Net loss attributable to common stockholders, basic	(21,304)	(21,518)	(40,933)	(21,470)
Net loss attributable to common stockholders, diluted	$ (21,304)	$ (21,518)	$ (40,933)	$ (21,470)
Weighted-average number of shares of common stock outstanding, basic	23,037,714	2,847,675	23,024,754	2,817,008
Weighted-average number of shares of common stock outstanding, diluted	23,037,714	2,847,675	23,024,754	2,817,008
Net loss per share attributable to common stockholders, basic	$ (0.92)	$ (7.56)	$ (1.78)	$ (7.62)
Net loss per share attributable to common stockholders, diluted	$ (0.92)	$ (7.56)	$ (1.78)	$ (7.62)